TB Drug Development

每年评估大约4,000至5,000种化合物对结核分枝杆菌的抗微生物生长抑制活性。改进、标准化和采用新的分析方法来确定化合物对休眠(缓慢生长、持久或静止)的结核分枝杆菌生物体的活性。每年评估大约1000种选定化合物抑制细胞内结核分枝杆菌复制。在感染的哺乳动物细胞培养测试系统中评估治疗药物对结核分枝杆菌的疗效。

Evaluate approximately 4,000 to 5000 compounds per year for antimicrobial growth-inhibition activity against Mycobacterium tuberculosis. Improve, standardize, and adopt new assays for determining the activity of compounds against dormant (slowly growing, persistent, or quiescent) M. tuberculosis organisms. Evaluate approximately 1000 selected compounds per year for inhibition of replication of intracellular M. tuberculosis. Evaluate therapeutic agents for efficacy against M. tuberculosis in an infected mammalian cell culture test system.